In vitro evidence for a new therapeutic approach in renal cell carcinoma.
Int Braz J Urol
; 34(4): 492-502, 2008.
Article
en En
| MEDLINE
| ID: mdl-18778501
ABSTRACT
PURPOSE:
Renal cell carcinoma (RCC) is the most lethal among the common urologic malignancies, comprising 3% of all human neoplasias; approximately 40% of patients eventually die of cancer progression. One third of patients who present with metastatic disease and up to 40% treated for localized disease generally experience recurrence. RCCs are characterized by high resistance to chemo-, radio- and immunotherapy. We recently discovered an endogenous enzymatic activity, which is particularly expressed in tumorigenic cell, endogenous non-telomerase reverse transcriptase (RT) of retrotrasposon / retroviral origin, as a specific target to induce proliferation arrest in a number of human carcinogenesis in vitro culture cell lines.METHODS:
To address this possibility, we have employed RCC primary cell culture testing pharmacological inhibition, in vitro, by two characterized non nucleosidic RT inhibitors, nevirapine and efavirenz; next, we assessed morphological effects and analyzed putative modulation on gene expression profile.RESULTS:
Both treatments reduced cell proliferation rate and induced morphological differentiation and gene expression reprogramming in different RCC analyzed tumor biomarkers.CONCLUSION:
In this study we describe a new potential therapeutic approach to obtain considerable future benefits in renal carcinoma cure and attempt to establish a new possible pharmacological therapy based on oral drugs administration in renal RCC treatment.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Inhibidores de la Transcriptasa Inversa
/
Nevirapina
/
Benzoxazinas
/
Neoplasias Renales
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Int Braz J Urol
Asunto de la revista:
UROLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Italia